24/7 Wall Street
26 Oct 2026, 11:51 UTC · 1h ago
AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30
Impact · against what's priced in
The recent FDA approvals for Juvmo and Skyrizi's Crohn's regimen provide incremental upside, as the market had previously declined to price in the full potential of the immunology pipeline beyond current trajectories. However, the expected 2027 revenue acceleration for Skyrizi and the modest initial ramp for Juvmo suggest these catalysts are slow-burn rather than immediate price drivers.
- ABBV+0.30
Challenges what's priced in
- The price assumes
The full upside of the immunology pipeline beyond current SKYRIZI and RINVOQ trajectories
The FDA approval of Skyrizi's subcutaneous induction regimen for Crohn's disease on October 23 provides tangible evidence of pipeline expansion that the market had previously declined to pay for.
What ABBV's price assumes · Sep 4
